These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Pharmacokinetic-pharmacodynamic modelling of the effect of Moxifloxacin on QTc prolongation in telemetered cynomolgus monkeys. Watson KJ, Gorczyca WP, Umland J, Zhang Y, Chen X, Sun SZ, Fermini B, Holbrook M, Van Der Graaf PH. J Pharmacol Toxicol Methods; 2011; 63(3):304-13. PubMed ID: 21419854 [Abstract] [Full Text] [Related]
6. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, Siegl PK, Strang I, Sullivan AT, Wallis R, Camm AJ, Hammond TG. Cardiovasc Res; 2003 Apr 01; 58(1):32-45. PubMed ID: 12667944 [Abstract] [Full Text] [Related]
9. Modelling of drug-induced QT-interval prolongation: estimation approaches and translational opportunities. Marostica E, Van Ammel K, Teisman A, Boussery K, Van Bocxlaer J, De Ridder F, Gallacher D, Vermeulen A. J Pharmacokinet Pharmacodyn; 2015 Dec 01; 42(6):659-79. PubMed ID: 26259721 [Abstract] [Full Text] [Related]
10. Oxycodone is associated with dose-dependent QTc prolongation in patients and low-affinity inhibiting of hERG activity in vitro. Fanoe S, Jensen GB, Sjøgren P, Korsgaard MP, Grunnet M. Br J Clin Pharmacol; 2009 Feb 01; 67(2):172-9. PubMed ID: 19159406 [Abstract] [Full Text] [Related]
12. QT prolongation and proarrhythmia by moxifloxacin: concordance of preclinical models in relation to clinical outcome. Chen X, Cass JD, Bradley JA, Dahm CM, Sun Z, Kadyszewski E, Engwall MJ, Zhou J. Br J Pharmacol; 2005 Nov 01; 146(6):792-9. PubMed ID: 16158069 [Abstract] [Full Text] [Related]
13. Comprehensive T wave morphology assessment in a randomized clinical study of dofetilide, quinidine, ranolazine, and verapamil. Vicente J, Johannesen L, Mason JW, Crumb WJ, Pueyo E, Stockbridge N, Strauss DG. J Am Heart Assoc; 2015 Apr 13; 4(4):. PubMed ID: 25870186 [Abstract] [Full Text] [Related]
14. Validation and Clinical Utility of the hERG IC50:Cmax Ratio to Determine the Risk of Drug-Induced Torsades de Pointes: A Meta-Analysis. Lehmann DF, Eggleston WD, Wang D. Pharmacotherapy; 2018 Mar 13; 38(3):341-348. PubMed ID: 29380488 [Abstract] [Full Text] [Related]
15. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs). Lu HR, Yan GX, Gallacher DJ. J Pharmacol Toxicol Methods; 2013 Mar 13; 68(2):250-259. PubMed ID: 23337247 [Abstract] [Full Text] [Related]
18. Differentiating multichannel block on the guinea pig ECG: Use of Tpeak-Tend and J-Tpeak. Skinner M, Hale E, Ceuppens P, Pollard C. J Pharmacol Toxicol Methods; 2021 Mar 13; 111():107085. PubMed ID: 34182121 [Abstract] [Full Text] [Related]